ESMO GI Congress 2015: Neuropilin1 may be Prognostic and Identify a Subgroup of Patients with Metastatic Colorectal Cancer who Benefit from fromTivozanib+ mFOLFOX6 Compared to Bevacizumab+ mFOLFOX6
TIVO-3: Final OS Analysis Of A Phase III, Randomized, Controlled, Multicenter, Open-Label Study To Compare Tivozanib To Sorafenib In Subjects With Metastatic Renal Cell Carcinoma (RCC)
